M T Voso

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. pmc Similarities and differences between therapy-related and elderly acute myeloid leukemia
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 3:e2011052. 2011
  2. pmc New treatments for myelodysplastic syndromes
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 2:e2010021. 2010
  3. pmc 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature
    M Greco
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 3:e2011011. 2011
  4. pmc Why methylation is not a marker predictive of response to hypomethylating agents
    Maria Teresa Voso
    Haematologica 99:613-9. 2014
  5. doi request reprint Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional
    Maria Teresa Voso
    Department of Hematology, Universita Cattolica S Cuore, Rome, Italy
    J Clin Oncol 31:2671-7. 2013
  6. doi request reprint Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
    Maria Teresa Voso
    Department of Hematology, Universita Cattolica S Cuore, Rome, Italy
    Eur J Haematol 90:345-8. 2013
  7. pmc Outcome of therapy-related myeloid neoplasms treated with azacitidine
    Luana Fianchi
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, 00168, Roma, Italy
    J Hematol Oncol 5:44. 2012
  8. doi request reprint Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Leukemia 22:1685-91. 2008
  9. ncbi request reprint Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Ann Oncol 18:1523-8. 2007
  10. ncbi request reprint Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Blood 103:698-700. 2004

Detail Information

Publications52

  1. pmc Similarities and differences between therapy-related and elderly acute myeloid leukemia
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 3:e2011052. 2011
    ..Given the unfavorable prognosis of elderly and t-MN and the similar clinical and molecular aspects, this is a promising field for implementation of new treatment protocols including alternative biological drugs...
  2. pmc New treatments for myelodysplastic syndromes
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 2:e2010021. 2010
    ..Other agents under development for the treatment of MDS include histone deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat...
  3. pmc 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature
    M Greco
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Mediterr J Hematol Infect Dis 3:e2011011. 2011
    ..Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start...
  4. pmc Why methylation is not a marker predictive of response to hypomethylating agents
    Maria Teresa Voso
    Haematologica 99:613-9. 2014
    ....
  5. doi request reprint Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional
    Maria Teresa Voso
    Department of Hematology, Universita Cattolica S Cuore, Rome, Italy
    J Clin Oncol 31:2671-7. 2013
    ..The definition of disease-specific prognostic scores plays a fundamental role in the treatment decision-making process in myelodysplastic syndrome (MDS), a group of myeloid disorders characterized by a heterogeneous clinical behavior...
  6. doi request reprint Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
    Maria Teresa Voso
    Department of Hematology, Universita Cattolica S Cuore, Rome, Italy
    Eur J Haematol 90:345-8. 2013
    ..4 months. Reasons for treatment discontinuation included comorbidities, infections, and patient choice. These findings illustrate the risk of prematurely terminating azacitidine therapy in MDS...
  7. pmc Outcome of therapy-related myeloid neoplasms treated with azacitidine
    Luana Fianchi
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, 00168, Roma, Italy
    J Hematol Oncol 5:44. 2012
    ..Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation...
  8. doi request reprint Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Leukemia 22:1685-91. 2008
    ..003 and 0.03, respectively), whereas GSTT1 and GSTM1 genotypes had no significant impact. The favorable impact of GSTP1(*)105 Val on RFS seems to be restricted to the subgroup of patients exhibiting a normal karyotype...
  9. ncbi request reprint Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Ann Oncol 18:1523-8. 2007
    ..Polymorphisms in genes involved in detoxification and DNA-repair pathways may modify the individual's risk for genomic damage, and, as a consequence, the risk of developing malignant diseases...
  10. ncbi request reprint Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Blood 103:698-700. 2004
    ..002) and with the presence of cytogenetic abnormalities (P =.02). Alteration in the apoptotic response due to the loss of DAP-kinase function may be an early event in the transformation pathway to secondary leukemia via myelodysplasia...
  11. ncbi request reprint In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
    M T Voso
    Department of Internal Medicine V, University of Heidelberg, and German Cancer Research Centre, Heidelberg, Germany
    Br J Haematol 109:729-35. 2000
    ..In conclusion, the addition of the CD20 antibody to chemotherapy ensured tumour depletion in vivo and allowed the collection of PBSCs devoid of tumour cells and with conserved engraftment capability...
  12. ncbi request reprint Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore and Dipartmento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Blood 100:2703-7. 2002
    ..003). In conclusion, individuals with GSTM1 or GSTT1 deletions (or deletions of both) may have an enhanced resistance to chemotherapy and a shorter survival...
  13. ncbi request reprint Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms
    Maria Teresa Voso
    German Cancer Research Center, Heidelberg, Germany
    Haematologica 87:918-25. 2002
    ..It was the objective of this study to define the contribution of the different mechanisms of action of rituximab on primary normal and malignant B-cells...
  14. doi request reprint Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Clin Cancer Res 15:5002-7. 2009
    ..We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher risk MDS...
  15. doi request reprint Epigenetic changes in therapy-related MDS/AML
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Largo A Gemelli 8, 00168Rome, Italy
    Chem Biol Interact 184:46-9. 2010
    ..However, how the epigenetic machinery is disrupted after chemo/radiotherapy and during secondary carcinogenesis is still unknown, warranting further studies...
  16. ncbi request reprint Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia
    L Fianchi
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Ann Oncol 19:128-34. 2008
    ..We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients...
  17. doi request reprint Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas
    S Hohaus
    Istituto di Ematologia e di Anatomia Patologica, Universita Cattolica S Cuore, Rome, Italy
    Ann Oncol 20:1408-13. 2009
    ..Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases...
  18. ncbi request reprint Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation
    A Leo
    Institute for Immunology and the Department of Internal Medicine, University Clinics of Heidelberg, Heidelberg, Germany
    Transfusion 40:632-6. 2000
    ..After allogeneic peripheral blood progenitor cell (PBPC) transplantation, a patient developed a severe hemolytic transfusion reaction due to passenger lymphocyte syndrome...
  19. ncbi request reprint Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
    S Hohaus
    Istituto di Ematologia e di Anatomia Patologica, Universita Cattolica S Cuore, Rome, Italy
    Ann Oncol 18:1376-81. 2007
    ..Cytokine expression can be altered by common single nucleotide polymorphisms (SNPs) in the 5'-promoter regions...
  20. ncbi request reprint Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S Cuore, 00168 Rome, Italy
    Clin Cancer Res 9:3435-40. 2003
    ....
  21. pmc Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia
    A Scardocci
    Istituti di Ematologia, DI, Universita Cattolica Sacro Cuore, L go A Gemelli 1, 00168 Roma, Italy
    Br J Cancer 95:1108-13. 2006
    ..0004), and to increased DNA methyltransferase DNMT3A (P=0.003) expression. Our data show that reduced BRCA1 expression owing to promoter hypermethylation is frequent in t-AML and that this could contribute to secondary leukaemogenesis...
  22. ncbi request reprint Telomerase activity in human hematopoietic progenitor cells
    S Hohaus
    Department of Medical Genetics, Universita Cattolica S Cuore, Rome, Italy
    Haematologica 82:262-8. 1997
    ..Recently, telomerase activity has been observed in human bone marrow (BM) and peripheral blood (PB) samples. The objective of our study was to further characterize the telomerase-expressing population in BM and PB...
  23. doi request reprint Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes
    Emiliano Fabiani
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, L go A Gemelli, Rome, Italy
    Leuk Res 33:1068-71. 2009
    ..R. 1.66; p=0.04) and to higher probability of overall survival in the low/intermediate-1 IPSS risk group (p=0.008). The GSTP1-Ile105Val polymorphism is likely to influence MDS risk and prognosis...
  24. pmc Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
    A Valencia
    Department of Hematology, Universita degli Studi di Firenze, AOU Careggi, Florence, Italy
    Leukemia 28:621-8. 2014
    ..049). Our results suggest that expression level of UCK1 is correlated with clinical outcome and may influence the clinical response to AZA treatment in patients with MDS. ..
  25. doi request reprint Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia
    T Ottone
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Leuk Res 36:474-8. 2012
    ..However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL...
  26. ncbi request reprint Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient
    L Fianchi
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo A Gemelli 8, 00168, Rome, Italy
    Infection 36:65-7. 2008
    ..Here we reported a case of G. capitatum pneumonia in a patient with plasma cell leukemia, successfully treated with antifungal combination with voriconazole and caspofungin and supportive therapy...
  27. ncbi request reprint Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Haematologica 89:664-70. 2004
    ..We studied the polymorphisms of cytochrome P450 CYP1A1 and glutathione S-transferase (GST), enzymes involved in the metabolism of carcinogens and anti-cancer drugs, as risk factors for adult AML...
  28. ncbi request reprint Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S Cuore, Largo A Gemelli 1, 00168 Rome, Italy
    Clin Cancer Res 11:2175-9. 2005
    ..We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma...
  29. ncbi request reprint Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects
    G Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy
    Cardiovasc Hematol Agents Med Chem 4:33-52. 2006
    ..Rituximab may cause tumour lysis syndrome. Alemtuzumab causes immunosuppression, increasing the risk of infection. GO may cause hepatotoxicity...
  30. doi request reprint Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes
    S K Hasan
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Neurology 76:1059-65. 2011
    ..We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ)...
  31. ncbi request reprint Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia
    M Garzia
    Dipartimento di Diagnostica Morfologica, Microbiologica, Molecolare e delle Malattie del Sangue, Catholic University of Sacred Heart, Rome, Italy
    Lab Hematol 13:30-3. 2007
    ..We report a case of a blastoid variant of MCL that developed in a patient with CML who achieved complete cytogenetic and molecular response to imatinib mesylate treatment...
  32. doi request reprint Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin
    Stefan Hohaus
    Institute of Hematology, Catholic University S Cuore, Rome, Italy
    J Clin Oncol 28:2538-43. 2010
    ..Cytokines play a pivotal role in Hodgkin's lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis...
  33. doi request reprint Incidence and susceptibility to therapy-related myeloid neoplasms
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo A Gemelli 8, 00168 Rome, Italy
    Chem Biol Interact 184:39-45. 2010
    ..In solid tumors, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of t-MN...
  34. doi request reprint Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Leuk Res 33:1352-6. 2009
    ..This analysis indicates that the genetic background can modulate plasma levels of IL-10, and ultimately prognosis in HL...
  35. pmc Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Med Chem 15:1274-87. 2008
    ..However, studies on leukemias have provided paradigmatic examples for the functional implications of the epigenetic alterations in cancer development and progression as well as their relevance for therapeutical targeting...
  36. ncbi request reprint DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 87:1324-41. 2002
    ..DNA methylation abnormalities have recently emerged as the most frequent molecular changes in hematopoietic neoplasms...
  37. ncbi request reprint Therapy-related leukemia and myelodysplasia: susceptibility and incidence
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Haematologica 92:1389-98. 2007
    ..In all cases the risk of t-MDS/AML drops sharply by 10 years after treatment...
  38. ncbi request reprint Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Clin Immunol 109:89-102. 2003
    ..Clinical trials are still ongoing, and preliminary data indicate for the first time that the natural history of MDS may be changed by a non-intensive treatment, characterized by an outstanding toxicity profile...
  39. ncbi request reprint Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S, Cuore, Rome, Italy
    Leuk Lymphoma 48:564-9. 2007
    ..In particular, GSTM1/T1 deletions identified patients with negative prognosis in the low (<3) FLIPI score group (p = 0.01). Larger prospective studies including homogeneously treated patients will be needed to confirm these results...
  40. doi request reprint PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
    L Cicconi
    Dipartimento di Biomedicina e Prevenzione, Universita degli Studi Tor Vergata, Roma, Italy
    Leukemia 30:1987-1992. 2016
    ..The data also suggest that ATRA-ATO may abrogate the negative prognostic impact of FLT3-ITD...
  41. doi request reprint Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms
    Mariangela Greco
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Blood Cells Mol Dis 45:181-5. 2010
    ....
  42. ncbi request reprint Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha
    Sergio Rutella
    Department of Hematology, Laboratory of Immunology, Catholic University Medical School, Rome, Italy
    Eur J Immunol 34:1291-302. 2004
    ..This novel mechanism of immune regulation effected by G-CSF might be therapeutically exploited for tolerance induction in autoimmune disorders...
  43. pmc Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
    Syed Khizer Hasan
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Blood 112:3383-90. 2008
    ..This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent...
  44. doi request reprint Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Lancet Oncol 9:352-8. 2008
    ....
  45. ncbi request reprint Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy
    Oncologist 11:285-91. 2006
    ..This study describes the clinical features and the natural history of nongastric marginal-zone lymphomas and highlights that the dissemination to lymph nodes and bone marrow is associated with a poorer outcome...
  46. ncbi request reprint The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia
    Maria Teresa Voso
    Haematologica 90:982-4. 2005
    ..We report that the polymorphic variant of the cytochrome P450 CYP1A1*2A, present in 11.3% of patients, is an independent unfavorable prognostic factor for failure-free and overall survival in patients with AML...
  47. ncbi request reprint Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma
    Stefan Hohaus
    Haematologica 89:751-2. 2004
    ..Treatment results were not superior to those achieved with conventional treatment (ABVD) in terms of complete remission and survival rates (progression-free survival and overall survival at 3 years: 66% and 91%, respectively)...
  48. ncbi request reprint Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre
    Annalaura Di Febo
    Leuk Lymphoma 44:1441-3. 2003
  49. ncbi request reprint In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study
    Giuseppe Leone
    Haematologica 89:634-6. 2004
    ..Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complete remission, 2 patients had a partial remission and the other 2 were resistant...
  50. ncbi request reprint DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma
    Maria Teresa Voso
    Istituti di Ematologia, Universita Cattolica Sacro Cuore, Rome
    Haematologica 91:1252-6. 2006
    ..Both mrakers were independent predictors of the disease status (p<0.001)...
  51. pmc CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha
    Steffen Koschmieder
    Department of Medicine, Hematology and Oncology, University of Munster, Münster Germany
    Blood 110:3695-705. 2007
    ..Because AML is characterized by arrested differentiation, our data suggest the inclusion of CDDO in the therapy of AML characterized by dysfunctional CEBPA expression...
  52. ncbi request reprint [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]
    P Bernardini
    Istituto di Medicina del Lavoro, Universita Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Roma
    Med Lav 96:119-25. 2005
    ..Health effects of occupational exposure to benzene are currently a problem, despite the fact that preventive measures have been in existence in Italy for more than 40 years...